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Abstract: Lamellarins, a family of hexacyclic pyrrole alkaloids originally isolated from 
marine invertebrates, display promising anti-tumor activity. They induce apoptotic cell 
death through multi-target mechanisms, including inhibition of topoisomerase I, interaction 
with DNA and direct effects on mitochondria. We here report that lamellarins inhibit 
several protein kinases relevant to cancer such as cyclin-dependent kinases, dual-
specificity tyrosine phosphorylation activated kinase 1A, casein kinase 1, glycogen 
synthase kinase-3 and PIM-1. A good correlation is observed between the effects of 
lamellarins on protein kinases and their action on cell death, suggesting that inhibition of 
specific kinases may contribute to the cytotoxicity of lamellarins. Structure/activity 
relationship suggests several paths for the optimization of lamellarins as kinase inhibitors. 
 
Keywords: lamellarin, kinase inhibitor, cyclin-dependent kinases, CK1, DYRK-1A, 
GSK-3 
 
Abbreviations: CDK, cyclin-dependent kinase; CK1, casein kinase-1; DYRK1A, dual-
specificity tyrosine-phosphorylated and regulated kinase 1A; FCS, fetal calf serum; GSK-
3, glycogen synthase kinase-3; GST, Glutathione-S-transferase; MBP, myelin basic 
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protein; MTS, 3- (4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2- (4-
sulfophenyl)-2H –tetrazolium; PARP, poly (ADP-ribose) polymerase. 
 
 
 
1. Introduction 
 
Marine organisms constitute an original and relatively untapped source of new enzymes and novel 
drugs of great biotechnological and pharmaceutical applications potential [reviewed in 1-2]. 
Cephalosporins, ara-C and ara-A represent the first molecules of marine origin which have reached the 
market. Quite a few molecules derived from marine organisms are now being investigated in clinical 
tests, essentially against cancer, inflammation, chronic pain and neurodegenerative diseases. In the 
cancer field, ecteinascidin 743 (yondelis), dehydrodidemnin B (aplidine), bryostatin-1, dolastatin and 
analogs, ziconotide (Prialt), discodermolide are some of the most advanced compounds. Other 
molecules, rather than being investigated as potential clinical drugs, have been developed as important 
pharmacological tools for cell biology, such as okadaic acid, kainic acid, latrunculin, tetrodotoxin, 
saxitoxin.  
Among the promising anti-cancer drug candidates derived from marine invertebrates is the family 
of lamellarins [reviewed in 3-5]. These hexacyclic pyrrole alkaloids were first isolated in 1985 from a 
prosobranch mollusk of the genus Lamellaria [6]. They were later extracted from and identified in 
various species of ascidians [7-14] and sponges [15-16] collected from very diverse areas. Over 38 
lamellarins (A-Z and α-γ) have been described [reviewed in 4, 5]. Following the discovery of the 
potent anti-proliferative and pro-apoptotic activities of lamellarins [17-24], their biological activities 
have been extensively studied. Lamellarins are potent inhibitors of topoisomerase I [19-21], they 
interact with DNA [19] and they target mitochondria directly and induce the release of cytochrome C 
and apoptosis-inducing factor (AIF) [23, 24]. They also function as multi-drug resistance reversal 
drugs [17, 22]. Furthermore, Lamellarin α 20-sulfate inhibits HIV-1 integrase [14, 26, 27]. 
In the course of screening for pharmacological inhibitors of disease-relevant protein kinases such as 
cyclin-dependent kinases (CDKs) [28, 29], glycogen synthase kinase-3 (GSK-3) [30], PIM1 [31], 
“dual-specificity, tyrosine phosphorylation regulated kinase 1A” (DYRK1A) [32-34], casein kinase 1 
(CK1) [35], we discovered that several lamellarins inhibit the catalytic activity of some of these 
kinases. We here report on the kinase inhibitory activity of 22 lamellarins [18, 36, 37] on 6 protein 
kinases. These lamellarins were also tested in parallel for their effects on the survival of human 
neuroblastoma SH-SY5Y cells and the expression of a selection of key proteins. The contribution of 
kinase inhibition to the anti-tumor properties of lamellarins is discussed. 
CDK1/cyclin B is essential for G1/S and G2/M phase transition of the cell cycle. Inhibition of 
CDK1/cyclin B leads to cell cycle arrest eventually leading ultimately to cell death. Deregulation of 
CDK5/p25 has been associated with neurodegenerative diseases including Alzheimer’s disease, 
therefore it was included in the panel of kinases tested. In addition to inactivating glycogen synthase, 
GSK-3α/ß is also implicated in control of the cellular response to DNA damage and is directly 
involved in Alzheimer’s disease. PIM-1 is up-regulated in prostate cancers. DYRK1A, suspected to 
play a role in Down’s syndrome and Alzheimer’s disease, is thought to participate in central nervous Mar. Drugs 2008, 6  516
 
 
system development, in growth control, and development. Likewise, CK1 is implicated in regulation 
of various physiological processes, and in diseases such as cancers and Alzheimer’s disease. 
 
2. Results and Discussion 
 
2.1. Lamellarins inhibit protein kinases 
 
While screening marine natural products for new chemical inhibitors of protein kinases, we found 
lamellarin D to display significant activity. We thus initially assembled a small collection of natural 
and synthetic lamellarin analogs (Table 1).  
 
Table 1. Structure of the lamellarins used in this study. A single (──) or a double (══) 
bond is present between C5 and C6, depending on the molecule. Me, methyl; i-Pr, 
isopropyl. 22: -OH at position 7. 
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#  Lamellarin  R1  R2  R3 R4 R5 R6 5-6 
1  lamellarin D  OH  OMe OH  OMe  OMe  OH  ══ 
2  lamellarin α OH  OMe OH  OMe  OMe  OMe  ══ 
3  di-H-lamellarin D  OH  OMe OH  OMe  OMe  OH  ── 
4  lamellarin H  OH  OH OH OH  OH  OH  ══ 
5  di-H-lamellarin H  OH  OH  OH  OH  OH  OH  ── 
6  lamellarin N  OH  OMe OMe  OH  OMe  OH  ══ 
7  lamellarin L  OH  OMe OMe  OH  OMe  OH  ── 
8  lamellarin G tri-
OMe 
OMe OMe OMe  OMe  OMe  OMe  ── 
9  lamellarin 3  OH  H  OH  OMe  OMe  OH  ══ 
10  lamellarin 4  H  OMe OH  OMe  OMe  OH  ══ 
11  lamellarin 5  OH  OMe OMe  OMe  OMe  OMe  ══ 
12  lamellarin 6  OH  OMe OH  H  OMe  OH  ══ 
13  lamellarin 7  OH  OMe H  OMe  OMe  OH  ══ 
14  lamellarin 8  H  H  OH  OMe  OMe  OH  ══ 
15  lamellarin 9  H  H  OH  OH  OH  OH  ══ 
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Table 1. Cont. 
 
16  lamellarin 11  H  H  OMe  OMe  OMe  OMe  ══ 
17  lamellarin 12  O-CH2-O  OMe  OMe  OMe  OMe  ══ 
18  lamellarin 33  Oi-Pr OMe Oi-
Pr 
OMe OMe Oi-Pr  ══ 
19  lamellarin 31  Oi-Pr OMe Oi-
Pr 
OMe OMe Oi-Pr  ── 
20  lamellarin 34  Oi-Pr OMe OMe  Oi-Pr OMe Oi-Pr  ══ 
21  lamellarin 32  Oi-Pr OMe OMe  Oi-Pr OMe Oi-Pr  ── 
22  lamellarin K  OH  OMe OH  OMe  OMe  OMe  ── 
 
All compounds were run on our kinase assay panel comprising CDK1/cyclin B, CDK5/p25, GSK-
3α/ß, PIM-1, DYRK1A, CK1. Results are presented in Table 2. They show that some lamellarins are 
potent inhibitors of various protein kinases. The limited number of lamellarin analogs precludes a solid 
structure/activity relationship study. Nevertheless, striking differences in kinase inhibitory activity are 
observed following minor changes at the lamellarin chemical structure. For example,  
‒  removal of the hydroxyl at R1 modestly modifies the activity (except GSK-3, DYRK1A and 
CK1), compare lamellarin D (1) and lamellarin 4 (10). 
‒  removal of the hydroxyl at R2 results in minor changes in activity (except DYRK1A and CK1), 
compare lamellarin D (1) and lamellarin 3 (9). 
‒  removal of the hydroxyl at R3 results in major reduction in activity, compare lamellarin D (1) 
and lamellarin 7 (13) 
‒  removal of the hydroxyl at R4 results in enhanced inhibitory activity, compare lamellarin D (1) 
and lamellarin 6 (12). 
‒  O-methylation at R6 results in massive loss of inhibitory activity, compare lamellarin D (1) and 
lamellarin α (2). 
‒  replacing the hydroxyl groups of lamellarin D (1) at R1, R3, and R6 by O-isopropyl completely 
abolishes inhibitory activity, see lamellarin 31 (18) and 33 (19). This is also the case when 
substituting hydroxyl to isopropyl at positions R1, R4, and R6 of lamellarin N (6), lamellarin 32 
(21) and 34 (20). 
‒  transposition of the substitutions at R3 and R4 of lamellarin D (1), resulting in lamellarin N (6), 
lead to 10-fold enhanced kinase inhibitory activity. 
‒  Reduction in activity due to saturation of D-ring double bond (C5=C6) has previously been 
reported to be due to loss of planarity and therefore steric hindrance in ATP pocket of targets 
[19]. Kinase inhibitory activities of lamellarins are generally reduced when the D-ring double 
bond is saturated, compare lamellarins D (1) with di-H-lamellarin (3), and lamellarins N (6) 
with lamellarin L (7). 
Altogether these results suggest complex but specific interactions between lamellarins’ susbstituents 
and their kinase targets. Co-crystal structure would be most helpful to understand these interactions 
and optimize lamellarins as kinase inhibitors.  
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Table 2. Biological activity of lamellarins. Each lamellarin was tested on 6 protein 
kinases. Enzyme activities were assayed as described in the Experimental section. Results 
are reported as IC50 values (expressed in µM) estimated from the dose-response curves. -, 
no inhibitory activity was detected (highest concentration tested is indicated in 
parentheses). Lamellarins were also tested for their effect on the survival of human 
neuroblastoma SH-SY5Y cells, using the MTS assay (IC50 values expressed in µM). The 
effect of some lamellarins on HeLa cells [18] is provided for comparison. Nt, not tested. 
# Lamellarin 
CDK1/ 
cyclin B 
CDK5
/ 
p25 
GSK
-3α/ß 
PIM
1 
DYRK1A CK1 
SH-
SY5Y 
HeLa 
[18] 
1  lamellarin  D  0.50  0.55 0.3 0.10  0.45  13.0  0.019  0.011 
2  lamellarin α  8.0  > 10  1.4  0.59  5.0  7.9  - (10)   
3  di-H-lamellarin  D  1.85  0.11 0.9 0.20  0.50  5.9  0.41  nt 
4  lamellarin H  - (10)  - (10)  9.5  - (10)  - (10)  5.3  0.45  > 100 
5  di-H-lamellarin H  - (10)  - (10)  0.67  - (10)  - (10)  5.2  2.55  nt 
6  lamellarin  N  0.070  0.025  0.005  0.055 0.035 -  (10) 0.025  nt 
7  lamellarin L  0.38  0.1  0.041  0.25  0.14  - (10)  0.7  nt 
8  lamellarin G tri-
OMe 
- (10)  - (10)  - (10)  - (10)  > 10  - (10)  - (100)  nt 
9  lamellarin  3  0.53  0.60 0.58 0.15  0.06  0.41  0.056  0.04 
10  lamellarin  4  2.0 0.6  0.05  0.05  0.08 1.3 0.79  0.85 
11  lamellarin 5  - (10)   - (10)  - (10)  2.0  - (10)  - (10)  8.0  2.5 
12  lamellarin  6  0.10  0.03 0.13 0.33  0.09  0.8  0.11  0.04 
13  lamellarin 7  4.3  2.1  2.1  - (10)  - (10)  - (10)  0.14  0.07 
14  lamellarin  8  5  0.9 2.2 0.7  1.0  -  (10) 2.65  4.0 
15  lamellarin 9  - (10)   - (10)  - (10)  - (10)  - (10)  - (10)  - (10)  1.1 
16  lamellarin 11  - (10)   - (10)  - (10)  - (10)  - (10)  - (10)  - (10)  5.7 
17  lamellarin 12  - (10)  - (10)  - (10)  - (10)  - (10)  - (10)  - (10)  > 100 
18  lamellarin 33  - (10)  - (10)  - (10)  - (10)  - (10)  - (10)  - (100)  nt 
19  lamellarin 31  - (10)  - (10)  - (10)  - (10)  - (10)  - (10)  - (100)  nt 
20  lamellarin 34  - (10)  - (10)  - (10)  - (10)  - (10)  - (10)  - (100)  nt 
21  lamellarin 32  - (10)  - (10)  - (10)  - (10)  - (10)  - (10)  - (100)  nt 
22  lamellarin K  - (10)  - (10)  - (10)  0.6  - (10)  6.0  - (30)  nt 
 
2.2. Selectivity of lamellarins 
 
Although most active compounds were active on all six kinases, a few lamellarins displayed 
apparent selectivity towards some kinases, suggesting that some degree of selectivity might be gained 
following the synthesis of more analogs. We next tested the selectivity of lamellarin N on the Cerep 
kinase selectivity panel (Table 3). Results show that lamellarin N does not inhibit all, but displays 
some selectivity for a few kinases, some of which are major cancer targets (VEGFR1/2, Flt-3, PDGFR, 
Lck, Lyn). Inhibition of protein kinases by the tested compounds observed could also possibly be due 
to non-specific interactions, raising the need for more analogues having a higher specificity for a Mar. Drugs 2008, 6  519
 
 
limited amount of kinases. Hopefully more selective lamellarin analogues can be designed when their 
interaction mode will be better understood. 
Table 3. Kinase inhibition selectivity of lamellarin N evaluated on the CEREP Kinase 
Selectivity Panel (44 kinases). Preparation and assay of kinases are described [44] 
(www.cerep.com). Enzymes were assayed in the presence of 10 µM lamellarin N, and 
kinase activities expressed as % of control kinase activity, i.e. in the absence of inhibitor. 
>80 % inhibition at 10 µM is underlined in grey. 
 
Protein Kinase  Activity (% of control)  SEM (%) 
Abl kinase (h)  61.4  0.8 
Akt1/PKBα (h)  104.6  2.6 
AMPKα 42.4  0.9 
BMX kinase (h) (Etk)  60.8  5.4 
Brk (h)  72.8  4.7 
CaMK2α (h)  38.2  2.2 
CaMK4 (h)  89.9  3.1 
CDC2/CDK1 (h) (cycB)  20.4  0.6 
CDK2 (h) (cycE)  57.1  0.3 
CHK1 (h)  93.3  1.9 
CHK2 (h)  47.6  0.6 
c-Met kinase (h)  92.1  1.6 
CSK (h)  47.4  2.5 
EphB4 kinase (h)  89.7  0.9 
ERK1 (h)  94.1  0.1 
ERK2 (h) (P42mapk)  79.9  1.4 
FGFR2 kinase (h)  19.8  0.6 
FGFR4 kinase (h)  62.5  0.3 
FLT-1 kinase (h) (VEGFR1)  4.0  0.2 
FLT-3 kinase (h)  0.4  0.4 
Fyn kinase (h)  20.1  1.2 
IGF1R kinase (h)  87.2  1.6 
IRK (h) (InsR)  46.7  1.6 
JNK 2 (h)  15.7  1.8 
KDR kinase (h) (VEGFR2)  7.4  1.1 
Lck kinase (h)  7.1  0.7 
Lyn kinase (h)  7.2  0.5 
MAPKAPK2 (h)  96.6  2.1 
MEK1/MAP2K1 (h)  81.5  1.0 
p38α kinase (h)  97.4  1.4 
p38δ kinase (h)  96.0  0.9 
p38γ kinase (h)  79.6  0.6 
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Table 3. Cont. 
 
PDGFRβ kinase (h)  1.8  0.4 
PDK1 (h)  89.8  0.6 
PKA (h)  80.0  4.6 
PKCα (h)  91.7  7.6 
PKCβ 1 (h)  102.0  1.8 
PKCγ (h)  94.1  1.9 
Ret kinase (h)  1.8  0.4 
ROCK2 (h)  103.3  0.9 
RSK2 (h)  44.5  0.5 
Src kinase (h)  56.2  0.4 
Syk (h)  97.1  0.7 
TRKA (h)  0.8  0.3 
 
2.3. Cell death induction by lamellarins 
 
We next tested the effects of each lamellarin, at an initial 10 µM concentration, on the survival of 
the neuroblastoma SH-SY5Y cell line after 48 h exposure (Table 2). Cell survival was estimated by the 
MTS reduction assay. Several compounds showed clear effects on the SH-SY5Y cell survival rate. A 
complete dose-response curve was performed for these active compounds after 24 h and 48 h exposure 
and the IC50 values were calculated (Table 2). The most active compounds were lamellarin D (1) (IC50: 
0.019 µM), lamellarin N (6) (IC50: 0.025 µM), lamellarin 3 (9) (IC50: 0.056 µM), and lamellarin 6 (12) 
(IC50: 0.11 µM). These lamellarins share a hydroxyl group at R1 and R6, an O-methyl group at R5, 
and a double bond between C5 and C6. As observed with the kinase inhibitory activity, a saturated C5-
C6 bond instead of a double bond leads to an decrease in activity (compare compounds 1 and 3, 4 and 
5, 6 and 7). Lamellarins which were totally inactive on kinases were devoid of effects on cell death. 
Altogether these first results suggest that kinase inhibition may contribute to the effects of lamellarins 
on cell proliferation and cell death. 
SH-SY5Y cells were next incubated with a range of lamellarin N concentrations or at 1 µM over 48 
hrs. Cell survival was monitored by the MTS reduction assay, cell death was assessed by the LDH 
release assay and caspase activation was measured using DEVD as a substrate (Figure 1). Kinetics and 
dose-response curves show that cells start dying rapidly after lamellarin N (half-life: 20 hours) at doses 
as low as 0.05 µM. 
Expression of p53, p21
CIP1 & Mcl-1 and PARP cleavage were next evaluated by Western blotting 
(Figure 2). Induction of PARP cleavage and p53 and p21 expression already takes place after 6 hour 
treatment with lamellarin N (Figure 2) and at concentration as low as 0.1 µM (data not shown). 
Interestingly, in contrast to the effects observed with roscovitine and other CDK inhibitors [42], the 
survival factor Mcl-1 is not down-regulated (Figure 2). Thus lamellarin N is able to trigger cell death 
in the presence of a constant level of the survival factor Mcl-1. As Mcl-1 confers resistance to the 
BCL-2 selective antagonist ABT-737 and to the proteasome inhibitor bortezomib [43], lamellarins 
might favorably combine with these treatments. Mar. Drugs 2008, 6  521
 
 
 
Figure 1. Dose- and time- dependent induction of cell death by lamellarin N. (A) 
Neuroblastoma SH-SY5Y cells were treated with lamellarin N at various concentrations. 
Cell death was measured by LDH release, cell survival was assessed by the MTS reduction 
assay, and caspase 3 activity was monitored as DEVDase activity. MTS and LDH assay 
were carried out 48 hours after treatment with lamellarin N. The caspase assay was carried 
out 24 hours after treatment. (B) Kinetics of cell survival, cell death and caspases 
activation following exposure of SH-SY5Y cells to 1 µM lamellarin N. Average of 3 
independent experiments performed in triplicate. The standard deviation (±SD) is indicated 
by error bars. 
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3. Conclusions 
 
In conclusion, we have identified new molecular targets of lamellarins. Combined with the well-
supported effects of lamellarins on topoisomerase 1, kinase inhibition may underlie the promising anti-
tumor properties of lamellarins. This work is now currently being extended in several directions: (i) 
synthesis and biological evaluation of new analogs, to allow the identification of more potent and more 
selective lamellarins as kinase inhibitors; (ii) optimization on the most cancer-relevant kinases; (ii) 
identification of the molecular mechanism of action of lamellarins on kinases (enzymological analysis, 
co-crystal structures); (iv) investigation of the contribution of kinase inhibition to the promising anti-
tumoral effects of lamellarins (and the synergy with previously identified mechanisms of action); (v) 
conversely, identification of lamellarin analogues devoid of kinase inhibitory properties but still able to 
interact with topoisomerase 2, possibly leading to compounds with less toxic side effects. Mar. Drugs 2008, 6  522
 
 
Identification of the key kinase targets of biologically active lamellarins or, in contrast, elimination of 
the kinase inhibition properties of lamellarins should be used to optimize this family of compounds 
towards selective and potent anti-tumor agents. 
 
Figure 2. Lamellarin N triggers PARP cleavage, p53 & p21
CIP1 upregulation, but not 
Mcl-1 down-regulation. SH-SY5Y cells treated at time 0 with 1 µM lamellarin N. Cells 
were harvested at different time-points and protein extracted for SDS-PAGE followed by 
Western blot analysis using antibodies directed against PARP, p53, p21
CIP1, or Mcl-1, as 
described in the materials and methods section. β-actin was used as loading control. “Ctrl” 
denoted untreated sample after 10 hours. 
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5. Experimental Procedures 
 
5.1. Chemistry 
 
Compounds  2,  4,  5 (lamellarin N), 6,  7 and 17-20 were synthesized employing Hinsberg-type 
pyrrole formation and Suzuki-Miyaura cross-couplings as the key reactions as previously described 
[37]. Compounds 1, 3 and 8-16 were synthesized by the previous methods in which the pyrrole core 
was constructed by N-ylide mediated intramolecular condensation [18, 36].  
 
5.2. Kinase preparation and assays 
 
Kinase activities were assayed in buffer A (10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM Tris-
HCl pH 7.5, 50 µg heparin/ml) or C (60 mM β-glycerophosphate, 15 mM p-nitrophenyl phosphate, 25 Mar. Drugs 2008, 6  523
 
 
mM MOPS (pH 7.2), 5 mM EGTA, 15 mM MgCl2, 1 mM dithiothreitol, 1 mM sodium vanadate, 1 
mM phenylphosphate, 0.1 % Nonidet P-40), at 30°C, at a final ATP concentration of 15 µM. Blank 
values were subtracted and activities calculated as pmoles of phosphate incorporated during a 30 min. 
incubation. The activities were expressed in % of the maximal activity, i.e. in the absence of inhibitors. 
Controls were performed with appropriate dilutions of dimethylsulfoxide. Unless otherwise stated, the 
P81 phosphocellulose assay was used. 
 
CDK1/cyclin B was extracted in homogenization buffer (60 mM ß-glycerophosphate, 15 mM p-
nitrophenylphosphate, 25 mM Mops (pH 7.2), 15 mM EGTA, 15 mM MgCl2, 1 mM DTT, 1 mM 
sodium vanadate, 1 mM NaF, 1 mM phenylphosphate, 10 µg leupeptin/ml, 10 µg aprotinin/ml, 10 µg 
soybean trypsin inhibitor/ml and 100 µM benzamidine) from M phase starfish (Marthasterias 
glacialis) oocytes and purified by affinity chromatography on p9
CKShs1-sepharose beads, from which it 
was eluted by free p9
CKShs1 as previously described [38]. The kinase activity was assayed in buffer C, 
with 1 mg histone H1 /ml, in the presence of 15 µM [γ-
33P] ATP (3,000 Ci/mmol; 1 mCi/ml) in a final 
volume of 30 µl. After 30 min. incubation at 30°C, 25 µl aliquots of supernatant were spotted onto 2.5 
x 3 cm pieces of Whatman P81 phosphocellulose paper, and, 20 sec. later, the filters were washed five 
times (for at least 5 min. each time) in a solution of 10 ml phosphoric acid/liter of water. The wet 
filters were counted in the presence of 1 ml ACS (Amersham) scintillation fluid. 
 
CDK5/p25 was reconstituted by mixing equal amounts of recombinant human CDK5 and p25 
expressed in E. coli as GST (Glutathione-S-transferase) fusion proteins and purified by affinity 
chromatography on glutathione-agarose (vectors kindly provided by Dr. L.H. Tsai) (p25 is a truncated 
version of p35, the 35 kDa CDK5 activator). Its activity was assayed with histone H1 in buffer C as 
described for CDK1/cyclin B.  
 
GSK-3α/β was purified from porcine brain by affinity chromatography on immobilized axin [39]. It 
was assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 µl 4 µM GS-1, a GSK-3 
selective substrate, (YRRAAVPPSPSLSRHSSPHQSpEDEEE, obtained from Millegen (31682 
Labège, France), in buffer A, in the presence of 15 µM [γ-
33P] ATP in a final volume of 30 µl. After 
30 min. incubation at 30°C, 25 µl aliquots of supernatant were processed as described above. 
 
PIM1 was expressed as a GST-fusion protein in E. coli and purified by affinity chromatography on 
glutathione-agarose. Its kinase activity was assayed for 30 min. with histone H1 in buffer C as 
described for CDK1/cyclin B.  
 
DYRK1A was expressed as a GST fusion protein in E. coli (vector kindly provided by Dr. W. 
Becker, Institute for Pharmacology and Toxicology, Aachen, Germany) and affinity purified on 
glutathione-agarose. Its kinase activity was assayed in buffer C, with 0.16 mg myelin basic protein 
(MBP)/ml, in the presence of 15 µM [γ-
33P] ATP in a final volume of 30 µl. After 30 min incubation at 
30°C, 25 µl aliquots of supernatant were treated as described above. 
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CK1 was purified from porcine brain by affinity chromatography on immobilized axin fragment 
[40]. The mixture of native CK1 isoforms (essentially CK1δ and CK1ε) was assayed in three-fold 
diluted buffer C, using 25 µM CKS peptide, a CK1 selective substrate (RRKHAAIGpSAYSITA, 
synthesized by Millegen (Labège, France). Assays were performed for 30 min. at 30°C, as described 
for GSK-3. 
 
5.3. Cell viability and cell death 
 
SH-SY5Y human neuroblastoma cells were grown in DMEM supplemented with 2mM L-glutamine 
(Invitrogen, Cergy Pontoise, France), plus antibiotics (penicillin-streptomycin) and a 10% volume of 
fetal calf serum (FCS) (Invitrogen). Cell viability was determined by means of the MTS (3- (4,5-
dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H -tetrazolium) reduction 
method as previously described [41]. Cell death was (also) assayed by LDH release.  Lactate 
dehydrogenase is a stable cytosolic enzyme that is released upon cell lysis [40]. SH-SY5Y cells were 
also subjected to caspase activity assays. These are based on cleavage of a synthetic caspase substrate 
DEVD (MP Biomedicals, 199423), a subtrate of active caspase 3/6/7. The assay was carried out 
according to manufacturer’s instructions [41]. 
 
5.4. Protein extraction, SDS-PAGE and Western Blotting 
 
At given time points and lamellarin doses, SH-SY5Y cells were harvested in phosphate buffered 
saline (PBS) with commercially available protease inhibitors (Roche, 11836145001). Cells were 
homogenized by sonication in homogenization buffer supplemented with 0.1% NP-40 and protease 
inhibitors. The homogenization buffer consist of: 25mM MOPS, 15mM EGTA, 15mM MgCl2, 1mM 
sodium orthovanadate, 1mM sodium fluoride, 60mM β-glycerophosphate, 2mM DTT, 15mM p-
nitrophenylphosphate, and 1mM phenyl phosphate-di-sodium salt (all reagents supplied by Sigma). 
Sonication retrieved proteins. Cellular proteins were subjected to electrophoresis in SDS 10% 
polyacrylamide gels and transferred to a PVDF membrane (Invitrogen). Membranes were incubated 
with primary antibodies directed against p53 (Santa Cruz Biotech, sc-263) (1:1000), p21
CIP1 
(Calbiochem, OP64) (1:1000) or poly (ADP-ribose) polymerase (PARP) (Santa Cruz Biotech, sc-
7150) (1:500). Appropriate secondary antibodies conjugated to horseradish peroxidase (Biorad) were 
added to visualize the proteins using the ECL detection system. 
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